Skip to content

Foundation Model for Post-MI Cardiovascular Event Alert Using Huawei Watch

Effect of Smartwatch Along With Foundation Model for the Monitoring and Management of Acute Myocardial Infarction Patients During Outpatient Cardiac Rehabilitation After Percutaneous Coronary Intervention: Protocol for a Randomised Controlled Multicentre Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07395648
Enrollment
1050
Registered
2026-02-09
Start date
2026-04-01
Completion date
2028-06-01
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Myocardial Infarction

Brief summary

The goal of this randomized controlled trial is to evaluate whether a HUAWEI smartwatch integrated with a foundation model can enhance daily monitoring and management of AMI patients during outpatient cardiac rehabilitation after PCI. Can a HUAWEI smartwatch with a foundation model improve daily monitoring/management of post-PCI AMI patients during 3-month outpatient CR, vs routine management or smartwatch without AI? Does the AI-enabled smartwatch (Intervention I) reduce 3-month cardiovascular-related hospital/emergency visits vs the other two groups? Do smartwatches (with/without AI) enhance quality of life and activity function post 3-month CR? Does the AI-enabled smartwatch lower 1-year major adverse cardiovascular events (MACEs) and related hospital/emergency visits vs other groups? How accurate is the AI-enabled smartwatch's alert system (vs hospital diagnostic results) for cardiovascular abnormalities? What is the usability of the AI-enabled smartwatch for patients and doctors? Participants will: Sign informed consent; complete baseline exams (MET, SF-36, 6-minute walk, exercise tolerance test) and questionnaires (demographics, medical history, medications). Receive 3-month outpatient CR. Attend follow-ups; report all adverse events promptly. Intervention I (AI-Enabled Smartwatch) group Wear the smartwatch continuously for 3 months (sleep wear recommended); actively collect ≥30s ECG via the watch's crown. Pause activity if heart rate exceeds anaerobic threshold; adjust exercise intensity if METs mismatch prescription. Contact doctors immediately upon receiving abnormality alerts (e.g., heart failure); follow expert recommendations for further care; complete usability questionnaires. Intervention II (Non-AI Smartwatch) group Wear the smartwatch continuously for 3 months (sleep wear recommended) to track activity/sleep, monitor real-time heart rate/MET. Pause activity if heart rate exceeds anaerobic threshold; adjust exercise intensity if METs mismatch prescription. Control Group Complete routine outpatient CR and follow-ups (no smartwatch use).

Interventions

DEVICESmartwatch + AI assisted

All patients will receive routine outpatient CR and follow-up. Subjects in the intervention group will be required to wear a smartwatch continuously for 3 months. For patients in Intervention group, the smartwatch will record the daily activities and sleep status. Furthermore, for patients in Intervention I group, the pre-trained foundation model will generate preliminary diagnostic suggestion based on the data collected by the smartwatch to remind the appearance of heart failure, myocardial ischemia, arrhythmia, abnormal blood pressure, and abnormal cerebral blood supply.

DEVICESmartwatch only

All patients will receive routine outpatient CR and follow-up. Subjects in the intervention group will be required to wear a smartwatch continuously for 3 months. For patients in Intervention group, the smartwatch will record the daily activities and sleep status.

DEVICEConventional care

All patients will receive routine outpatient CR and follow-up.

Sponsors

Tongji Hospital
Lead SponsorOTHER
Beijing Anzhen Hospital Affiliated to Capital Medical University
CollaboratorUNKNOWN
Fengtai Rehabilitation Hospital of Beijing Municipality (Tieying Hospital)
CollaboratorUNKNOWN
Beijing Aerospace General Hospital
CollaboratorOTHER
First Affiliated Hospital of Harbin Medical University
CollaboratorOTHER
The Third People's Hospital of Chengdu
CollaboratorOTHER
Second Hospital of Jilin University
CollaboratorOTHER
Qilu Hospital of Shandong University
CollaboratorOTHER
Guangdong Provincial People's Hospital
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

1. Aged more than equal to 18 years, less than 69 years. 2. Discharged within 6 months after PCI for acute myocardial infarction, and haven't received outpatient cardiac rehabilitation; 3. 40%≤EF≤50% and NT-pro BNP ≤500 pg/mL; 4. With the history of hypertension; 5. Voluntarily joined and signed the informed consent.

Exclusion criteria

1. With contraindication for rehabilitation activities include: unstable angina, uncontrolled hypertension (systolic blood pressure\>180 mmHg and/or diastolic blood pressure\>110 mmHg in a quiet state), severe symptomatic heart valve stenosis, uncontrolled heart rate increase (\>130 beats/minute), uncontrolled heart failure, third degree atrioventricular block (without pacemaker implantation), active pericarditis or myocarditis, presence of newly formed embolism (pulmonary or systemic circulation), aortic dissection, acute thrombophlebitis, acute systemic disease or fever, other metabolic abnormalities (such as acute thyroiditis, electrolyte imbalance, uncorrected blood glucose abnormalities or insufficient blood volume), and severe psychological disorders; 2. Patients who have a pre-planned staged revascularization procedure (e.g., planned second coronary intervention) following their initial PCI for AMI. 3. Tattoos or other substances that affect optical signals on the wrist. 4. Coronary heart disease patients at high risk. 5. Pregnant women or women planning to become pregnant within the next year. 6. Severe arrhythmia, including third degree atrioventricular block, ventricular escape rhythm, severe sinus bradycardia, sick sinus syndrome, supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter. 7. Physical disability, blindness, and deafness.

Design outcomes

Primary

MeasureTime frameDescription
Major adverse eventsThree months.Occurrence of major adverse events (MI, stroke or death)

Secondary

MeasureTime frameDescription
Motor functionThree monthsAssessed by metabolic equivalent of task
Quality of lifeThree monthsAssessed by 36-Item Short Form Health Survey
Exercise toleranceThree monthsAssessed by 6-minute walking distance

Contacts

CONTACTYucong Zhang, M.D.
u201110541@hust.edu.cn86 13627115411
STUDY_CHAIRCuntai Zhang, PhD

Wuhan TongJi Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026